Schering's contrast media sales down 8%
This article was originally published in Clinica
German company Schering's contrast media sales fell 8% to DM 364 million ($238 million) in the first quarter of 1996. The company says that encouraging growth for its contrast agent, Ultravist, failed to compensate for Iopamiron sales losses in Japan, partly caused by exchange rate effects. The X-ray contrast agent, Isovist 280, was temporarily suspended in October last year, following delayed-onset allergic skin reactions (see Clinica No 675, p 9).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.